Display options
Cite
Iwamoto J, Sato Y, Uzawa M, et al. Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Ther Clin Risk Manag. 2010;6:593-600doi: 10.2147/TCRM.S15812.
Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2010). Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Therapeutics and clinical risk management, 6593-600. https://doi.org/10.2147/TCRM.S15812
Iwamoto, Jun, et al. "Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures." Therapeutics and clinical risk management vol. 6 (2010): 593-600. doi: https://doi.org/10.2147/TCRM.S15812
Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. Ther Clin Risk Manag. 2010 Dec 06;6:593-600. doi: 10.2147/TCRM.S15812. PMID: 21206758; PMCID: PMC3012448.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2010 Dec 06;6:593-600. doi: 10.2147/TCRM.S15812.

Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Therapeutics and clinical risk management

Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto

Affiliations

  1. Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo.

PMID: 21206758 PMCID: PMC3012448 DOI: 10.2147/TCRM.S15812

Abstract

PURPOSE: A retrospective study based on a conventional medical practice was performed to evaluate the outcome of alendronate treatment for four years in Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

METHODS: Twenty-nine Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures (mean age at baseline 61.0 years) who had been treated with alendronate for over four years in our outpatient clinic were studied. Lumbar spine or total hip bone mineral density (BMD) was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of bone-specific alkaline phosphatase were monitored during the four-year treatment period.

RESULTS: Urinary NTX and serum bone-specific alkaline phosphatase levels decreased (-44.4% at three months and -61.2% at four years, respectively) and lumbar spine and total hip BMD increased (+13.9% and +9.2% at four years, respectively), compared with baseline values. No serious adverse events were observed, including osteonecrosis of the jaw, femoral diaphysis atypical fractures, or atrial fibrillation.

CONCLUSION: To our knowledge, this is the first report of the outcome of alendronate treatment for four years in Japanese men with an increased risk for fractures. Alendronate suppressed bone turnover and increased lumbar spine and total hip BMD from baseline over the course of the four-year treatment period without causing any severe adverse events in Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Keywords: alendronate; bone mineral density; fracture risk; men; osteopenia; osteoporosis

References

  1. N Engl J Med. 2008 Mar 20;358(12):1304-6 - PubMed
  2. Rheumatol Int. 2004 Mar;24(2):110-3 - PubMed
  3. N Engl J Med. 2000 Aug 31;343(9):604-10 - PubMed
  4. J Bone Miner Res. 2003 Aug;18(8):1547-53 - PubMed
  5. J Bone Miner Metab. 2005;23(3):238-42 - PubMed
  6. J Bone Miner Metab. 2005;23(5):382-8 - PubMed
  7. Arch Intern Med. 2008 Apr 28;168(8):826-31 - PubMed
  8. J Bone Miner Res. 2004 Aug;19(8):1250-8 - PubMed
  9. Lancet. 1996 Dec 7;348(9041):1535-41 - PubMed
  10. JAMA. 1998 Dec 23-30;280(24):2077-82 - PubMed
  11. Rev Endocr Metab Disord. 2001 Jan;2(1):45-64 - PubMed
  12. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12 - PubMed
  13. Osteoporos Int. 2002 Mar;13(3):195-9 - PubMed
  14. J Bone Miner Metab. 2001;19(6):331-7 - PubMed
  15. Eur J Clin Invest. 1992 Aug;22(8):542-5 - PubMed
  16. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155 - PubMed
  17. Calcif Tissue Int. 2003 Aug;73(2):133-9 - PubMed
  18. J Bone Miner Metab. 2009;27(2):168-74 - PubMed
  19. Clin Drug Investig. 2004;24(6):333-41 - PubMed
  20. Lancet. 2002 Jun 1;359(9321):1929-36 - PubMed
  21. Osteoporos Int. 1999;10(3):183-92 - PubMed
  22. J Bone Miner Metab. 2005;23(2):97-104 - PubMed
  23. Osteoporos Int. 2005 Jun;16(6):581-9 - PubMed
  24. Rheumatol Int. 2006 Mar;26(5):427-31 - PubMed
  25. Clin Rheumatol. 2007 Feb;26(2):161-7 - PubMed

Publication Types